Otsuka Pharmaceutical, PDL BioPharma deal

Otsuka will acquire IV Busulfex busulfan from PDLI for $200 million in cash. The drug is marketed in more than 40 countries, including the U.S. and Canada, for use in combination with cyclophosphamid...